HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - HCW Biologics (NASDAQ:HCWB)

Core Insights - HCW Biologics Inc. has regained compliance with Nasdaq listing rules, allowing continued access to public capital markets for advancing its immunotherapeutic drugs [1][2] Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies aimed at treating diseases linked to chronic inflammation, particularly age-related and senescence-associated diseases [2] - The company's lead product candidate, HCW9302, is a first-in-kind interleukin-2 fusion molecule currently in a Phase 1 clinical study for alopecia areata [2] Product Pipeline - HCW Biologics has identified two preclinical lead product candidates: - HCW11-018b ("Big BiTE"), a tetra-valent T-cell engager designed to improve manufacturability and safety for treating solid tumors [2] - HCW11-040, a pembrolizumab-based immune checkpoint inhibitor enhanced with additional moieties to neutralize TGF-β and activate immune responses [2] Business Development - The company has entered into two licensing agreements for exclusive worldwide rights to some proprietary molecules, indicating a focus on business development as part of its clinical strategy [2]